French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol.
Databases, Factual
Drug Prescriptions
/ statistics & numerical data
France
/ epidemiology
Humans
Incidence
National Health Programs
/ statistics & numerical data
Prescription Drug Misuse
/ prevention & control
Prospective Studies
Sleep Aids, Pharmaceutical
/ pharmacology
Substance-Related Disorders
/ epidemiology
Zolpidem
/ pharmacology
addictovigilance
change in law
impact
secured prescription
substance misuse
zolpidem
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
28 06 2019
28 06 2019
Historique:
entrez:
1
7
2019
pubmed:
1
7
2019
medline:
9
6
2020
Statut:
epublish
Résumé
In recent years, data collected by the French Addictovigilance Network have shown the potential for abuse and addiction associated with zolpidem (the most sold hypnotic drug in France). Since 10 April 2017, new regulations have come into force that require zolpidem to be prescribed on special secure prescription pads, in order to reduce the risk of abuse or misuse. This measure has far-reaching repercussions that are not only limited to the consumption of zolpidem but also extend to the usage of sedative medication on a whole. The objective of the ZOlpidem and the Reinforcement of the Regulation of prescription Orders (ZORRO) study is to evaluate the overall impact of the new regulatory framework requiring zolpidem to be prescribed on special secure prescription pads. Three axes will be evaluated: the number of consumers, the type of consumption (chronic use versus occasional use, problematic consumption versus non-problematic use) and the consumption of other sedative molecules.The study has been registered in the Protocol Registration and Results System under the number NCT03584542 at stage "Pre-results". The ZORRO study is an epidemiological, observational, national multicentre, non-controlled, prospective research project supported by the French National Agency for Medicines and Health Products Safety. The evaluation of the impact of the regulatory framework change relative to zolpidem will be done according to two axes: via an epidemiological study of the French National Health Insurance database and by the implementation of field studies of prescribers and consumers of zolpidem. The Nantes Research Ethics Committee (Groupe Nantais d'Ethique dans le Domaine de la Santé), the Committee for the Protection of the Population and the Committee of Expertise in Research, Studies and Evaluations in the Field of Health approved this study. Results will be presented in national and international conferences and submitted to peer-reviewed journals. NCT03584542; Pre-results.
Identifiants
pubmed: 31256026
pii: bmjopen-2018-027443
doi: 10.1136/bmjopen-2018-027443
pmc: PMC6609064
doi:
Substances chimiques
Sleep Aids, Pharmaceutical
0
Zolpidem
7K383OQI23
Banques de données
ClinicalTrials.gov
['NCT03584542']
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e027443Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Subst Use Misuse. 2015 Feb;50(3):350-7
pubmed: 25458710
Fundam Clin Pharmacol. 2018 Jun;32(3):306-322
pubmed: 29436015
Expert Opin Drug Saf. 2017 Sep;16(9):1063-1069
pubmed: 28649864
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
Drugs Aging. 2013 Jun;30(6):383-99
pubmed: 23553512
Therapie. 2008 Jan-Feb;63(1):55-65
pubmed: 18387277
Therapie. 2015 Mar-Apr;70(2):113-31
pubmed: 25858567
Therapie. 2012 Jul-Aug;67(4):397-404
pubmed: 23110841
J Addict Dis. 2014;33(1):15-23
pubmed: 24467433
Eur J Clin Pharmacol. 2013 Nov;69(11):1965-72
pubmed: 23877252
Addiction. 2003 Oct;98(10):1371-8
pubmed: 14519173
Br J Clin Pharmacol. 2007 Aug;64(2):198-209
pubmed: 17324242